基于FDG-PET肿瘤残余摄取III 期非小细胞肺癌患者的适应性放疗或标准放疗：一项多中心随机对照2期试验

文章预览

SCI 3 September 2024 Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [¹⁸F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial (Lancet Oncol, IF: 41.6) Vera P, Thureau S, Le Tinier F, et al: Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial. Lancet Oncol 25:1176–1187, 2024 Background 背景 Thoracic radiation intensification is debated in patients with stage III non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of a boost radiotherapy dose up to 74 Gy in a functional sub-volume given according to on-treatment [18F]fluorodeoxyglucose ([18F]FDG)-PET results. 在 III 期非小细胞肺癌(NSCLC)患者中， ………………………………